ERBB2 and breast carcinoma: The novel agent trastuzumab deruxtecan (humanised monoclonal antibody anti-human HER2-topoisomerase I inhibitor payload conjugate) shows promise, with significant overall response rates and progression-free survival benefits for patients with brain metastasis from HER2-positive breast cancer in a single-arm phase II trial [52].